[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Barnet Dulaney Perkins Eye Centers\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100589356",false,"NCT06953349","Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis","Real-World Efficacy of Hydrus Microstent With OMNI Surgical System in Combination With Phacoemulsification: a Retrospective Analysis","Inclusion Criteria:\n\n* Subjects with h\u002Fo CEIOL\u002FOMNI\u002FHydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data\n* have Glaucoma\n\nExclusion Criteria:\n\n* Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.\n* Patients with refractory CME or CME persisting 3 months or more post-operatively\n* Patients with incomplete IOP, medication logs or VF data within post-operative period\n* Prior incisional surgery or MIGS","ALL","18 Years",{"count":18,"type":19},300,"ESTIMATED","OBSERVATIONAL","Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis",[23],"Open-Angle Glaucoma",[25,26,27],"Hydrus Microstent","OMNI Surgical System","Phacoemulsification","RECRUITING","2025-04-29",{"date":31,"type":32},"2025-05-01","ACTUAL",{"date":34,"type":32},"2025-03-31",{"date":36,"type":19},"2025-12-31",{"name":38,"class":39},"Barnet Dulaney Perkins Eye Centers","NETWORK",1,{"id":42,"slug":4,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":10,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100587857","NCT06933836","DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma","How Does First Line Treatment With DSLT Perform in Treatment-naïve Patients With Newly Diagnosed Primary Open Angle Glaucoma","Inclusion Criteria:\n\n* Primary open angle glaucoma\n* Patients age 30 or greater with an IOP of 18-26 mmHg\n* Mild to moderate POAG patients (mild or moderate according to the AAO PPP Guidelines)\n* DSLT procedure\n\nExclusion Criteria:\n\n* History of prior glaucoma treatment - this includes past medication use (in either eye), previous lasers or incisional surgery\n* Angle closure patients\n* Ocular Hypertension\n* Baseline VF MD of worse than -12dB\n* Uncontrolled systemic microvascular disease (eg. HTN, DM)\n* Subjects with peri-limbal findings (e.g. melanosis, tumors, extensive pterygium, significant senile arcus and pterygium)","30 Years",{"count":49,"type":19},55,"DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.",[52],"Open Angle Glaucoma (OAG)",[54,55,56],"Glaucoma","DSLT","Interocular Pressure","2025-04-16",{"date":59,"type":32},"2025-04-18",{"date":34,"type":32},{"date":62,"type":19},"2027-12-31",{"name":38,"class":39},""]